Dare Bioscience, Inc.

Published Phase 1 data in Sexual Medicine strengthen the scientific foundation for Daré Bioscience’s proprietary topical Sildenafil Cream, 3.6%. At the 71 mg topical dose, mean maximum plasma concentration of sildenafil was approximately 187-fold lower than following a 50 mg oral dose. Publication expands peer-reviewed clinical evidence supporting Daré Bioscience’s proprietary topical Sildenafil Cream formulation

Announces that its pre-recorded presentation for the H.C. Wainwright 28th Annual Global Investment Conference is now available for on-demand

New NIH award will provide approximately $908,000 in year-long support of preclinical development, with potential for an additional future-year grant of approximately $1.3 million. DARE-PTB2 is an early-stage, investigational program focused on developing a potential new therapeutic approach for the prevention of preterm birth.

Video webcast now available.

Daré’s proprietary formulation of topical sildenafil cream, 3.6% was well tolerated across all evaluated doses in the clinical study, with minimal systemic exposure. Company continues activities necessary to advance its Sildenafil Cream toward the FDA’s 505(b)(2) regulatory pathway* while in parallel launching DARE to PLAY™ Sildenafil Cream, the 503B compounded version of its proprietary sildenafil cream formulation**. DARE to PLAY Sildenafil Cream prescription dispensing and initial product revenue expected to commence in Q3 2026

President & CEO, Sabrina Martucci Johnson, discusses the Company’s shift to commercial stage, upcoming revenue opportunities, Ovaprene’s positive interim Phase 3 results and what could drive value over the next 12–18 months

National recognition comes as Daré Bioscience advances a multi-product women’s health strategy across commercialization, clinical development and first-in-category innovation